Hematological parameters showed positive change after treatment
Neurophysiological assessments indicated enhanced nerve function post-therapy
Abstract
To the best of our knowledge, this is the first patient with Waldenström-associated CANDA with clinical, hematological, and neurophysiological benefit after zanubrutinib therapy.